SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs admitted affair with a business executive and the Nvidia boards independent investigation have drawn attention, with traders debating whether the unverified espionage allegations and potential leadership fallout pose a serious risk or are an overreaction unrelated to Nvidias AI business. Many are buying the selloff on confidence in the companys fundamentals, while others remain cautious about the investigation and possible CEO succession concerns.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is selling off after a weaker-than-expected Q3 report, with traders focused on the revenue decline, slowing commercial uptake and possible future dilution. The reaction is mixed: critics question execution and the cash outlook, while bullish traders argue the positive BCG-naive trial result and Israeli approval support the longer-term Anktiva story.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp pre-earnings rally ahead of TTDs Q3 report has traders debating whether hopes for a turnaround and possible short covering are driving the move; others remain cautious given concerns about slowing growth and weak guidance.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clovers Q3 earnings beat and improved full-year outlook, alongside a profitable quarter and strong membership growth, are fueling renewed buying and a push to hold above $5. Traders are divided over whether the gains can stick, with some focused on the companys growth and others disappointed by the lack of concrete Counterpart Health software revenue updates.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is in focus ahead of its quarterly results as traders weigh the Eli Lilly agreement to offer branded obesity drugs through its platform against concerns that the shift could pressure margins. The sharp decline has fueled speculation about disappointing results or an earnings leak, while others see the partnership and potential growth as reasons to stay bullish.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics BRIUMVI-driven quarterly beat and raised revenue outlook are drawing attention, but shares have fallen as traders debate a sell-the-news reaction versus a buying opportunity. The upcoming Phase 3 readout for subcutaneous BRIUMVI is widely viewed as the next major catalyst.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Jefferies Buy initiation and favorable Phase III prostate cancer data are drawing attention to Candels planned BLA filing for CAN-2409. Bulls see the results and recent immune-profile data as support for the regulatory case, while skeptics question filing execution, manufacturing readiness, financing needs and management transparency.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Debate over allegations of Webulls China ties and the fallout from a congressional report and securities lawsuits dominates discussion, with traders attributing the stocks weakness to a lingering China-related risk discount. Some see the upcoming earnings report and the companys growth as potential confidence builders, while skeptics say the overhang and poor performance versus peers remain unresolved.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Traders are linking ARWRs sharp decline to weak early sales for rival Ioniss Tryngolza, raising concerns about the commercial outlook for Arrowheads Redemplo despite some arguing its data and product profile are stronger. Others point to Arrowheads high cash burn and possible financing needs as added pressure.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs stronger-than-expected quarterly results and raised full-year revenue outlook are driving attention, with traders also pointing to expanding backlog and quantum-computing demand. Bulls see evidence of commercial momentum, while skeptics question dilution, cash burn and how much growth came from the SkyWater acquisition, keeping the reaction volatile.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HUM Stock Soars, ALHC Sinks As CMS Star Ratings Redraw 2028 Bonuses

Equity

Humana’s largest Medicare Advantage contract, covering more than 2 million members, rose from 3.5 stars to 4, putting it back above the bonus threshold.


ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It

The Medicare Advantage insurer had already faced skepticism after its second-quarter report. Tuesday’s comments reinforced that picture.


CLOV Stock Hits Over 2-Month High As Humana Deal Buzz Builds Ahead Of Investor Conferences 

Humana listed Counterpart Health among the vendors for its provider-performance and quality programs.

A Court Order Sent CLOV Stock To Over 4.5-Year Highs – Retail Says The Implications Could Be Industry-Wide

A District Court in Georgia ordered the Centers for Medicare & Medicaid Services to recalculate Clover’s 2026 Medicare star rating, following which it was raised to 4.5 from 3.5

Caseys General Stores Upbeat Q4 Earnings, Joins Applied Optoelectronics, Clover Health Investments And Other Big Stocks Moving Higher On Wednesday

US stocks down, Dow Jones fell 150 pts on Wed. Caseys General Stores Inc (CASY) shares up 14.4% after beating earnings. Other big gainers incl. CBRL, PLBL, RXT, YB, AXTI, AAOI, LMND, CLOV, TGTX, CRDO, CBRS, HOOD, FLNC, LITE, TTMIread more...

Clover Health Q1 Earnings Meet Estimates, Sales Beat, Membership Rises

CLOV posts 62% revenue growth in Q1 as Medicare Advantage membership surges and AI-driven care initiatives boost profitability.

Clover Health Investments (NASDAQ:CLOV) Releases Earnings Results, Misses Estimates By $0.02 EPS

Clover Health Investments (NASDAQ:CLOV - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.02). Clover Health Investments had a negative return on equity of 25.17% and a negative net...

Clover Health Investments Q1 Earnings Call Highlights

Clover Health Investments (NASDAQ:CLOV) reported first-quarter 2026 results that management said demonstrated the ability to combine rapid Medicare Advantage growth with GAAP profitability as the company continues scaling its technology-driven care model.

Membership growth and GAAP profitability
Ch...

Clover Health Investments, Corp. (CLOV) Meets Q1 Earnings Estimates

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 0.00% and +5.85%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Butterfly Network, Inc. (BFLY) Reports Q1 Loss, Beats Revenue Estimates

Butterfly Network (BFLY) delivered earnings and revenue surprises of +25.00% and +2.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of $0.03
• Reported revenue of $759.3M up 52.88% YoY
• Clover Health improved Full Year 2026 guidance: $2.97B, $25M, $540M, and $75M.

Clover Health reported higher SG&A and Adjusted SG&A as a share of revenue, while its disclosures identify policy-related financial exposure and risks to maintaining or improving Star Ratings.

Clover Health delivered higher revenue and gross profit with GAAP net income, grew Medicare Advantage membership, and cited strong product positioning, a 5 Star PPO rating, and nation-leading HEDIS performance.

UBS Global Healthcare Conference

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Alignment Healthcare’s largest California contract, H3815, fell from 4 stars to 3.5.</li><li>Aetna said more than 69% of its Medicare Advantage members are in 2027 plans rated 4 stars or higher, and President Steve Nelson said the results “highlight our distinction in the market.”</li><li>Crossing 4 on CMS star rating unlocks bonus payments that raise the federal money an insurer receives per member.</li></ul><p>Humana (HUM) shares surged as much as 13% in after-hours trading Thursday after the Centers for Medicare &amp; Medicaid Services released 2027 Medicare Advantage star ratings, a quality scorecard that decides which plans earn extra federal bonus payments, while Alignment Healthcare (ALHC) tumbled 23% after its largest contract fell below that cutoff.</p><p>CVS Health fell about 3% in extended trading, and Clover Health rose about 10%.</p><h2 class="st-heading-2">Why The Stars Move The Stocks</h2><p>Medicare Advantage is the private version of Medicare. CMS scores each contract from 1 to 5 stars on measures such as clinical outcomes, member experience, and how the plan is run. The 4-star mark is the cutoff that matters to investors. Crossing it unlocks bonus payments that raise the federal money an insurer receives per member. Dropping below it takes that bonus away.</p><p>The ratings published Thursday do not change this year’s results. They feed payments in 2028, which is why a single half-star move on a large contract can be worth hundreds of millions of dollars.</p><h2 class="st-heading-2">Humana Clears The Bonus Line</h2><p>Humana was the clearest winner. Its largest Medicare Advantage contract, covering more than 2 million members, rose from 3.5 stars to 4, putting it back above the bonus threshold, CMS data showed.</p><p>The rebound matters because Humana was hit hard the last time CMS published ratings. In October 2024, the share of its members in plans rated 4 stars or higher fell from 94% to 25%, after a large contract dropped from 4.5 stars to 3.5. That cut the bonus payments the company was set to receive in 2026. Thursday’s recovery puts that large contract back in line for bonuses in 2028.</p><h2 class="st-heading-2">Alignment And CVS Lose Ground</h2><p>Alignment Healthcare moved the other way. Its largest California contract, H3815, fell from 4 stars to 3.5. That contract accounted for about 81% of membership, so the downgrade knocked most of the company off the bonus list even though six of its seven rated contracts still scored 4 stars or higher, including three at 4.5. Dawn Maroney, president of Alignment Health, said the California rating “is inconsistent with that performance” and that the company “intend[s] to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review,” while remaining confident it can return the contract to at least 4 stars.</p><p>CVS, through its Aetna unit, also lost ground. Aetna said more than 69% of its Medicare Advantage members are in 2027 plans rated 4 stars or higher, and President Steve Nelson said the results “highlight our distinction in the market” and give the company confidence it can return to “appropriate margins.” The smaller stock move reflected a broader book than Alignment’s, so a slip on part of it does not rewrite the whole company’s 2028 revenue.</p><p>Clover Health said CMS gave the plans covering about 98% of its members a 5-star rating for 2027, the score that sets 2028 payments. A smaller plan scored 4.5 stars. The 5-star score leaves out 20 measures a federal judge told CMS not to count in a May ruling that the agency has appealed. With those measures included, Clover said, the larger plans would have scored 4.5 stars.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around HUM and ALHC was 'bullish' at the time of writing.</p><p>While <a class="mention" data-mention="$HUM" data-symbol-id="HUM" href="https://stocktwits.com/symbol/HUM" target="_blank">HUM stock</a> has gained 51% year-to-date, CVS added 11%, and CLOV 95%. ALHC, in the meantime, has fallen 56%</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/t-tmus-vz-stocks-plunge-after-hours-as-space-x-buys-800-m-hz-spectrum-for-starlink-mobile/cZDUxmJRBV5">T, TMUS, VZ Stocks Plunge After-Hours As SpaceX Buys 800 MHz Spectrum For Starlink Mobile</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

 Stethoscope with medicare form with parts list. Source: Getty Images

Humana’s largest Medicare Advantage contract, covering more than 2 million members, rose from 3.5 stars to 4, putting it back above the bonus threshold.

Alignment Healthcare Inc

CVS Health Corp

Humana Inc

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits Polls

Investors are obsessively tracking the repeated attempts to break and hold the key $5 psychological support level amid intense price action.

Shareholders are celebrating the latest positive earnings report while debating why the stock is struggling to maintain upward momentum.

Retail investors are venting frustrations over perceived dark pool manipulation, short selling, and persistent stop-loss raiding by market makers.

Hopes remain high that an official rollout of the company's AI-driven Counterpart Health platform will trigger a massive re-valuation.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.05	--	--	N/A
Q3 '26	-$0.01	$0.01	297.36%	BEAT
Q2 '26	$0.04	$0.05	29.40%	BEAT
Q1 '26	$0.07	$0.07	5.69%	BEAT
Q4 '25	-$0.10	-$0.05	50.48%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLOV Earnings

Latest Earnings Results: Q3 '26

Historical Earnings